Hologic, Inc. $HOLX Shares Sold by TD Asset Management Inc

TD Asset Management Inc reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 3.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,484,641 shares of the medical equipment provider’s stock after selling 45,676 shares during the quarter. TD Asset Management Inc owned about 0.67% of Hologic worth $100,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in HOLX. Winnow Wealth LLC purchased a new position in shares of Hologic in the 3rd quarter worth about $26,000. Root Financial Partners LLC purchased a new stake in shares of Hologic during the 3rd quarter worth about $27,000. SJS Investment Consulting Inc. increased its position in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares in the last quarter. Loomis Sayles & Co. L P purchased a new position in Hologic in the second quarter valued at approximately $33,000. Finally, Smartleaf Asset Management LLC lifted its position in Hologic by 168.5% during the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HOLX. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Morgan Stanley upped their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research note on Friday, November 21st. Two analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $78.42.

Hologic Trading Down 0.0%

NASDAQ:HOLX opened at $75.34 on Thursday. The stock has a market cap of $16.82 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.49. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The business’s 50-day simple moving average is $74.94 and its 200 day simple moving average is $72.04.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 earnings per share. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.